IVERIC bio, Inc. – NASDAQ:ISEE

Financial Health
0
1
2
3
4
5
6
7
8
9

IVERIC bio stock price monthly change

+5.58%
month

IVERIC bio stock price quarterly change

+63.63%
quarter

IVERIC bio stock price yearly change

+314.47%
year

IVERIC bio key metrics

Market Cap
5.51B
Enterprise value
2.96B
P/E
-17.71
EV/Sales
N/A
EV/EBITDA
-16.22
Price/Sales
N/A
Price/Book
6.25
PEG ratio
0.48
EPS
-1.67
Revenue
N/A
EBITDA
-231.35M
Income
-212.13M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

IVERIC bio stock price history

IVERIC bio stock forecast

IVERIC bio financial statements

IVERIC bio, Inc. (NASDAQ:ISEE): Profit margin
Jun 2022 0 -48.29M
Sep 2022 0 -41.95M
Dec 2022 0 -51.27M
Mar 2023 0 -70.61M
IVERIC bio, Inc. (NASDAQ:ISEE): Earnings per share (EPS)
2023-05-15 -0.59768 -0.53
IVERIC bio, Inc. (NASDAQ:ISEE): Debt to assets
Jun 2022 319756000 26.81M 8.38%
Sep 2022 331790000 72.26M 21.78%
Dec 2022 666823000 132.16M 19.82%
Mar 2023 613407000 136.36M 22.23%
IVERIC bio, Inc. (NASDAQ:ISEE): Cash Flow
Jun 2022 -35.90M -17.64M 2.80M
Sep 2022 -41.11M 3.38M 49.71M
Dec 2022 -49.23M -1.86M 374.30M
Mar 2023 -50.59M 39.27M 2.58M

IVERIC bio alternative data

IVERIC bio, Inc. (NASDAQ:ISEE): Employee count
Aug 2023 163
Sep 2023 163
Oct 2023 163
Nov 2023 163
Dec 2023 163
Jan 2024 163
Feb 2024 163
Mar 2024 163
Apr 2024 163
May 2024 163
Jun 2024 163
Jul 2024 163

IVERIC bio other data

94.68% -5.32%
of ISEE is owned by hedge funds
113.31M -5.96M
shares is hold by hedge funds

IVERIC bio, Inc. (NASDAQ:ISEE): Insider trades (number of shares)
Period Buy Sel
Aug 2022 0 12272
Nov 2022 0 122916
Dec 2022 0 62910
Jan 2023 0 26897
Feb 2023 0 51214
Mar 2023 0 20000
Apr 2023 0 110000
May 2023 0 94714
Jun 2023 0 20000
Jul 2023 0 20000
Transaction Date Insider Security Shares Price per share Total value Source
Option
WESTBY KEITH officer: SVP, Chief Operating O..
Stock Option (right to buy) 20,000 $2.94 $58,800
Option
WESTBY KEITH officer: SVP, Chief Operating O..
Common Stock 20,000 $2.94 $58,800
Sale
WESTBY KEITH officer: SVP, Chief Operating O..
Common Stock 20,000 $39.45 $789,000
Option
SBLENDORIO GLENN director, officer: Chief Execut..
Common Stock 11,084 $13.22 $146,486
Option
SBLENDORIO GLENN director, officer: Chief Execut..
Stock Option (right to buy) 11,084 $13.22 $146,486
Option
WESTBY KEITH officer: SVP, Chief Operating O..
Stock Option (right to buy) 20,000 $2.94 $58,800
Option
WESTBY KEITH officer: SVP, Chief Operating O..
Common Stock 20,000 $2.94 $58,800
Sale
WESTBY KEITH officer: SVP, Chief Operating O..
Common Stock 20,000 $37.87 $757,400
Option
GRAVES ADRIENNE L director
Restricted Stock Units 14,588 N/A N/A
Option
HENDERSON JANE director
Common Stock 14,588 N/A N/A
Patent
Application
Filling date: 21 Feb 2022 Issue date: 9 Jun 2022
Application
Filling date: 14 Jun 2021 Issue date: 2 Dec 2021
Application
Filling date: 16 Nov 2018 Issue date: 10 Jun 2021
Application
Filling date: 6 Jun 2019 Issue date: 19 Dec 2019
Insider Compensation
Mr. Glenn P. Sblendorio M.B.A. (1956) Chief Executive Officer & Director
$1,250,000
Dr. Pravin U. Dugel M.D. (1964) Pres $780,650
Mr. David F. Carroll (1966) Senior Vice President, Chief Financial Officer & Treasurer $633,580
Mr. Keith Westby M.B.A. (1975) Senior Vice President & Chief Operating Officer
$621,220
Wednesday, 20 September 2023
prnewswire.com
Monday, 18 September 2023
prnewswire.com
Thursday, 17 August 2023
prnewswire.com
Friday, 4 August 2023
prnewswire.com
Friday, 28 July 2023
GuruFocus
Monday, 1 May 2023
Bloomberg Markets and Finance
Proactive Investors
Investors Business Daily
Barrons
Market Watch
Monday, 6 March 2023
24/7 Wall Street
Friday, 18 November 2022
InvestorPlace
Saturday, 5 November 2022
Seeking Alpha
Friday, 4 November 2022
Business Wire
Investors Business Daily
Monday, 17 October 2022
24/7 Wall Street
Tuesday, 27 September 2022
Business Wire
Wednesday, 7 September 2022
Zacks Investment Research
Seeking Alpha
Tuesday, 6 September 2022
InvestorPlace
Wednesday, 3 August 2022
InvestorPlace
Tuesday, 26 July 2022
Seeking Alpha
Thursday, 21 July 2022
Business Wire
Wednesday, 6 July 2022
GuruFocus
Thursday, 23 June 2022
Seeking Alpha
Wednesday, 8 June 2022
Seeking Alpha
Tuesday, 17 May 2022
Business Wire
Wednesday, 4 May 2022
Seeking Alpha
Wednesday, 9 March 2022
Benzinga
Tuesday, 8 March 2022
Seeking Alpha
  • When is IVERIC bio's next earnings date?

    Unfortunately, IVERIC bio's (ISEE) next earnings date is currently unknown.

  • Does IVERIC bio pay dividends?

    No, IVERIC bio does not pay dividends.

  • How much money does IVERIC bio make?

    IVERIC bio has a market capitalization of 5.51B. IVERIC bio made a loss 175.75M US dollars in net income (profit) last year or -$0.53 on an earnings per share basis.

  • What is IVERIC bio's stock symbol?

    IVERIC bio, Inc. is traded on the NASDAQ under the ticker symbol "ISEE".

  • What is IVERIC bio's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of IVERIC bio?

    Shares of IVERIC bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are IVERIC bio's key executives?

    IVERIC bio's management team includes the following people:

    • Mr. Glenn P. Sblendorio M.B.A. Chief Executive Officer & Director(age: 69, pay: $1,250,000)
    • Dr. Pravin U. Dugel M.D. Pres(age: 61, pay: $780,650)
    • Mr. David F. Carroll Senior Vice President, Chief Financial Officer & Treasurer(age: 59, pay: $633,580)
    • Mr. Keith Westby M.B.A. Senior Vice President & Chief Operating Officer(age: 50, pay: $621,220)
  • How many employees does IVERIC bio have?

    As Jul 2024, IVERIC bio employs 163 workers.

  • When IVERIC bio went public?

    IVERIC bio, Inc. is publicly traded company for more then 11 years since IPO on 25 Sep 2013.

  • What is IVERIC bio's official website?

    The official website for IVERIC bio is ivericbio.com.

  • Where are IVERIC bio's headquarters?

    IVERIC bio is headquartered at 8 Sylvan Way, Parsippany, NJ.

  • How can i contact IVERIC bio?

    IVERIC bio's mailing address is 8 Sylvan Way, Parsippany, NJ and company can be reached via phone at +60 9 474 6755.

IVERIC bio company profile:

IVERIC bio, Inc.

ivericbio.com
Exchange:

NASDAQ

Full time employees:

163

Industry:

Biotechnology

Sector:

Healthcare

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

8 Sylvan Way
Parsippany, NJ 07054

CIK: 0001410939
ISIN: US46583P1021
CUSIP: 46583P102